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Abstract 
Mesenchymal stem cells (MSCs) are an accepted candidate for cell-based therapy of multiple diseases. The interest in 
MSCs and their possible application in cell therapy have resulted in a better understanding of the basic biology of 
these cells. Recently, like aggregation and transforming growth factor beta (TGFβ) delivery, hypoxia has been 
indicated as crucial for complete chondrogenesis. The aim of this study was to test different culture conditions for 
directing stem cell differentiation into the chondrogenic lineage in vitro by testing different TGFβ superfamily 
members into the culture media under normoxic conditions. All chondrogenic culture conditions used allowed the 
differentiation of bone marrow-MSCs (BM-MSCs) into chondrogenic lineage. Chondrogenic induction capacity 
depended on the growth factor added to the culture media. In particular, the chondrogenic culture condition that better 
induced chondrogenesis was the medium that included the combination of three growth factors: bone morphogenetic 
protein-2 (BMP-2), BMP-7 and TGFβ-3. In this culture media, differentiated cells showed the highest levels 
expression of two markers of chondrogenesis, SOX9 and COL2A1, compared to the control points (p < 0.05, two-
tailed t test). In our experimental conditions, the combination of BMP-2, BMP-7 and TGFβ-3 was the most effective 
in promoting chondrogenesis of BM-MSCs. These results underline the importance of determining in each 
experimental design the best protocol for in vitro directing stem cell differentiation into the chondrogenic lineage. 
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Introduction 
Mesenchymal stem cells (MSCs) are undifferentiated, nonhematopoietic, multipotent adult stem cells that 
have the capability to renew themselves and differentiate into different cell types (fat, bone, cartilage and 
hematopoietic supporting stroma) as described abundantly in literature (Ryden et al. 2003; Pittenger, 
2008; Hombach-Klonisch et al. 2008; Diaz-Prado et al. 2011). 
The most commonly used tissue source for the isolation of MSCs is the bone marrow as discussed by 
different authors (Conget and Minguell, 1999; Pittenger et al. 1999). Three minimal criteria, established 
by the International Society for Cellular Therapy in 2006 (Dominici et al. 2006), defines bone marrow-
MSCs (BM-MSCs): adherence to plastic, specific surface antigen expression and multipotent 
differentiation potential. BM-MSCs represent a promising cell resource for tissue engineering and cell-
based therapies. 
The use of autologous or allogenic stem cells is suggested by Jung et al. (2009) and coauthors as an 
alternative therapeutic approach for treatment of cartilage defects . Cartilage tissue engineering has the 
potential to provide cartilaginous constructs capable of restoring the normal function of articular cartilage 
as described by Buckwalter and Mankin (1998). To improve the repair of cartilage by tissue engineering, 
several cell treatments have been developed with the aim of forming a repair tissue with structural, 
biochemical, and functional characteristics equivalent to those of natural articular cartilage as described 
by Díaz Prado et al. (2011). 
The use of differentiated chondrogenic progenitors has to be chosen on the use of undifferentiated 
stem cells. Chondrogenesis is the process by which MSCs differentiate towards chondrocyte, as resumed 
by Goldring et al. (2006). Different protocols allow the induction of BM-MSCs chondrogenic 
differentiation. To mimic mesenchymal condensation and cell–cell interactions, MSCs are cultured in 
high density aggregates as described in different papers (Cicione et al. 2010; DeLise et al. 2000; 
Johnstone et al. 1998). Derfoul reported the necessity of culture MSCs in medium containing 
dexamethasone to induce chondrogenic differentiation (Derfoul et al. 2006) and Tuli the necessity to add 
growth factors belonging to the TGFβ superfamily that constitute the earliest signals in chondrogenic 
condensation (Tuli et al. 2003). 
Several growth factors are known to influence the anabolic and catabolic processes of chondrocytes. 
Therefore, a number of these growth factors have been used in cartilage tissue engineering studies in vitro 
to promote the chondrogenic phenotype, to stimulate extracellular matrix production and to promote 
chondrogenesis of MSCs, as reviewed by Kock recently (Kock et al. 2012). Among others, TGFβ-3, 
BMP-2 and osteogenic protein 1 (OP-1 or BMP-7) stimulate the synthesis of proteoglycans and collagens 
matrix components as described by Spagnoli (2008) and are necessary for different steps during 
chondrogenesis as shown by Pizette and Niswander (2000). 
A number of studies (Blaney Davidson et al. 2007; Bobick et al. 2009; Yoon and Lyons, 2004) have 
demonstrated that TGFβ superfamily polypeptides (TGFβs and BMPs) induce the expression of 
chondrocyte specific genes, such as Collagen type 2 and SOX9, suggesting their critical role of signaling 
in chondrogenesis. 
In the last years, many studies have been focused on finding better culture conditions to differentiate 
MSCs towards mature chondrocytes. The use of chondrocyte-conditioned medium proposed by Hwang et 
al. (2008) or the co-culture of MSCs with chondrocytes described by Chen et al. (2009) have been 
described to be able to drive MSCs chondrogenic differentiation. 
In this study we examined the capacity of three different growth factors (BMP-2, BMP-7 and TGFβ-
3), alone or in combinations, to induce chondrogenic differentiation in normoxic conditions. We defined 
the optimal conditions, between the stimuli used, to obtain chondrogenic differentiation of BM-MSCs 
aggregate cultures by the use of histological, immunohistochemical analysis and real-time (qPCR) 
technique. We determined the expression levels of different genes involved in chondrogenesis 
corresponding to the mature chondrocyte phenotype (COL2A1, SOX9 and aggrecan). 
  
Materials and methods 
Isolation and culture of MSCs 
The BM samples used to isolate MSCs were obtained from three patients (mean age 69 years, range 55–
82 years) undergoing total hip replacement. The donors were not selected; the samples submitted were 
processed as they arrived at the laboratory. This study was approved by the institutional review board, 
and informed consent was obtained from all subjects in the study. 
BM-derived mesenchymal stem cells (BM-MSCs) were isolated by washing the BM with 50 mL of 
Dulbecco’s modified Eagle’s medium (DMEM), 10 % fetal bovine serum (FBS) with a gauge needle (BD 
Microbalance™ 3, Oxford, Ireland) and a 20 mL syringe (Kendall Monoject Syringe, Istambul, Turkey) 
as previously described (Hermida-Gomez et al. 2011). The resulting cell suspension was filtered through 
a sterile 40 µm cell strainer and centrifuged at 300xg for 8 min. Isolated BM cells were cultured in 
monolayer in DMEM, 20 % FBS, 1 % penicillin and streptomycin (P/S) (all from Sigma-Aldrich, St. 
Louis, MO, USA) until 80 % confluent. Pre-plating for 15 min in the first two passages eliminated any 
fibroblasts remaining in the culture as suggested by Richler and Yaffe (1970). 
The cells were cultured and expanded in monolayer until the beginning of the differentiations 
experiments at 37 °C in a humidified atmosphere containing 5 % CO2. At this point, when cells reached 
80 % of confluence, they were trypsinized, washed and submitted both to phenotypical analysis and to 
differentiation experiments. 
Phenotypic characterization using flow cytometry 
At the 3rd passage, after culture expansion, the cells were trypsinized, washed and analyzed by flow 
cytometry for hematopoietic and MSCs markers as described before (Cicione et al. 2013). The antibodies 
listed in supplementary Table 1 were used for these experiments. A minimum of 25,000 cell events per 
assay were acquired on a FACsCalibur flow cytometer (BD Biosciences, Madrid, Spain). Data were 
analyzed using Cell Quest software (BD Biosciences) and the results were expressed as positive 
percentage. 
Multipotential characterization 
At 3rd passage the cells were differentiated towards three different lineages (adipocyte, osteoblast and 
chondrocyte) in humidified atmosphere with 5 % CO2. The culture conditions used to induce each 
differentiation are described in the following paragraphs. 
Adipogenic and osteogenic differentiation 
At 3rd passage BM-MSCs were detached using trypsin–EDTA (Sigma-Aldrich, St. Louis, MO, USA), 
seeded at 1.5 × 105 cells/cm2 in a chamber slide (BD Falcon, France) and cultured in growth medium until 
confluence in normoxic conditions. Adipogenesis was induced by culturing for 3 weeks in hMSC 
Commercial Adipogenic Differentiation Medium (Lonza, Biowhittaker, Belgium), following the 
manufacturer’s instructions. Osteogenesis was induced by culture for 3 weeks in normoxic conditions in 
hMSC Commercial Osteogenic Differentiation Medium (Lonza, Biowhittaker, Belgium), following the 
manufacturer’s instructions. Each differentiation point was compared with a control point that 
corresponded to cells cultured for the same period of time with DMEM and 20 % FBS. Differentiation 
was assessed trough histological and real-time PCR (qPCR) techniques. 
Chondrogenic differentiation 
Chondrogenesis was assessed using the micropellet formation (2.5 × 105 cells) technique first described 
by Johnstone et al. (1998), with some modifications. BM-derived cells from the third passage were 
detached using trypsin–EDTA and centrifuged at 300g for 10 min. The resulting pellet was treated for 
14 days to induce chondrogenic differentiation. The medium used for the first 2 days contained DMEM 
with 15 % FBS, supplemented with 5 mg/mL ascorbic acid (AA), 1/1,000 monotioglycerol (MTG), and 
1 % P/S to promote chondroprogenitor condensation. This medium was replaced by DMEM with 15 % 
knockout (KO) serum (Gibco, Madrid, Spain), 1 % P/S and supplemented with 5 mg/mL AA, 10 µM 
dexamethasone, 6 µg/mL transferrin, 1 × 10−7 M retinoic acid, and the use of three different growth 
factors alone or in combination: TGFβ-3 1 ng/mL (Prospec-Tany Technogene Ltd., Rehovot, Israel); 
TGFβ-3 10 ng/mL; BMP-2 10 ng/mL (Prospec-Tany Technogene Ltd., Rehovot, Israel); BMP-7 
10 ng/mL (Prospec-Tany Technogene Ltd., Rehovot, Israel); TGFβ-3 1 ng/mL + BMP-2 
10 ng/mL + BMP-7 10 ng/mL. All the differentiation points were compared to cells grown in DMEM 
with 15 % KO serum. The culture medium was changed every 3–4 days. After 14 days, cell aggregates 
were directly frozen for RNA extraction or embedded in Tissue-Tech OCT compound (Sakura Finetek) 
and frozen for histological and immunohistochemical techniques. The presence of hyaline cartilage-
characteristic molecules, such as type II collagen and proteoglycans, were detected by histological, 
immunohistochemical and qPCR techniques as described below. 
Histologic analyses 
For adipogenesis evaluation, differentiation was confirmed by detection of cytoplasmic lipid droplets by 
Oil Red O staining after cell fixation in 4 % paraformaldehyde. Quantification of Oil Red O-positive cells 
was performed using analiSIS1 software (version D; Olympus, Germany). 
For osteogenesis evaluation, differentiation was analyzed by Alizarin Red staining after cell fixation 
in 4 % paraformaldehyde, to assess the presence of calcium deposits. Quantification of Alizarin Red-
positive cells was performed using analiSIS1 software (version D; Olympus, Germany). 
For chondrogenesis evaluation, 4 µm-thick frozen sections of aggregates were stained with 
hematoxylin and eosin (HE), Masson´s trichrome (MT), toluidine blue (TB) and safranin O (SaO) for 
proteoglycans and collagens. 
Immunohistochemical analyses 
For chondrogenesis evaluation, 4 µm-thick frozen sections were incubated with primary antibodies to 
detect the presence of types I (Abcam, Cambridge, UK), II (Chemicon, Australia) and X (Sigma Aldrich 
Quimica, Spain) collagens and metalloproteinase 13 (Thermo Fisher Scientific, Spain) (supplementary 
table 2). The peroxidase/DAB ChemMateTM DAKO EnVision™ detection kit (Dako, Barcelona, Spain) 
was used to determine antigen–antibody interactions. Negative staining controls were achieved by 
omitting the primary monoclonal antibody. Samples were visualized using an optical microscope. 
Quantification of the immunostaining for Col II was performed using analiSIS1 software (version D; 
Olympus, Germany). 
RNA isolation, cDNA (complementary DNA) synthesis and reverse transcription-PCR analysis (qPCR) 
Isolation of total RNA from cell cultures was accomplished using Trizol Reagent (Invitrogen, Barcelona, 
Spain), following the manufacturer´s protocol as described before (Cicione et al. 2013). RNA was 
assessed for quantity at 260 nm using a NanoDrop™ spectrophotometer (Thermo Scientific, Madrid, 
Spain). The A260/A280 ratio was calculated to assess quality and purity. Total RNA (1 µg) was further 
processed or stored at -80°C until used (Table 1). 
Total RNA underwent DNase digestion (Fermentas, Spain) for complete removal of DNA 
contamination. Subsequently, the reverse-transcription reaction was performed on 1 µg of total RNA 
using SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen™, Spain), following the 
manufacturer instructions as described before (Cicione et al. 2010). Samples were stored at −20 °C before 
the amplification of target cDNAs. Positive and negative controls were included in each experiment. 
Real-time PCR analysis (qPCR) was performed on a LightCycler® 480 Instrument (Roche, 
Mannheim, Germany) to study mRNA expression of the genes implicated in chondrogenesis (SOX9, 
aggrecan, COL1A1 and COL2A1), osteogenesis (ALP, OP) and adipogenesis (FABP4, APM1, and LPL). 
For this purpose the primers shown in Table 1 were used. 
The primers were purchased from Roche (Mannheim, Germany). The TATA box binding protein gene 
(TBP) was used as the internal control housekeeping gene to normalize the amount of target cDNA. 
Data analysis was performed using LightCycler 480 Relative Quantification software (Roche). 
Relative levels of expression were calculated by the 2−ΔΔCt method. Each assay was done at least in 
triplicate and included marker-positive and marker-negative controls and reagent with no template 
controls. Each data was normalized against the housekeeping gene. For each gene expression, we 
assigned the value 1 to the lowest level of expression and the values were measured as relative expression 
levels (REL). 
RNA extraction, reverse transcription-PCR assay setup and post reverse transcription-PCR product 
analysis were carried out in separate dedicated rooms to prevent cross-contamination. 
Statistical analysis 
Each experiment was repeated at least three times. The statistical significance of the differences between 
mean values was determined using a two-tailed t test; p < 0.05 was considered significant. Results are 
expressed as the mean ± standard error (mean ± SE) and mean ± standard deviation (mean ± SD) 
Results 
Isolation of BM-MSCs and characterization of cultured expanded cells 
Spindle-shaped bipolar cells attached to the flask were observed at the first medium change at 48 h of 
culture. We expanded, differentiated and analyzed the surface antigens expression and multipotentiality 
of the cells isolated from three donors. 
Phenotypic analysis 
At the third passage, at the beginning of the differentiation experiments, the BM-MSCs were 
characterized according to the expression of surface markers using flow cytometry. Table 2 shows data 
for age, gender and surface marker expressions obtained doing the mean value between the three BM-
MSCs donors. The cells displayed very similar expression of surface antigen expression and were 
negative for the expression of CD34, CD45 and STRO-1. In the table, each antigen expression value is 
expressed as positive percentage and the range of its expression is reported. CD73 and CD44 antigens 
were co-expressed at 94 % ± 0.05. CD105 was expressed at 96 % ± 0.12 when alone and co-expressed 
with CD106 at 24 % ± 0.14. CD166 was expressed at 92 % ± 0.06. The percentage of CD90 expression 
was around 95 % ± 0.02 and of CD29 was around 94 % ± 0.03. Our cultured cells expressed CD117 at 
23 % ± 0.38 and SSEA4 at 83 % ± 0.09.  
Table 1 Sequences of qPCR primers used for the amplification of human mRNA genes implicated in chondrogenesis 
Gene name Forward primer (5′-3′) Reverse primer (5′-3′) mRNA ID number 
    
SOX9 gtacccgcacttgcacaac tcgctctcgttcagaagtctc NM_000346 
COL2A1 gtgtcagggccaggatgt tcccagtgtcacagacacagat NM_001844 
AGG gcctacgaagcaggctatga gcacgccataggtcctga BC036445 
COL1A1 gtgatgctggtcctgttggt caccatcgtgagccttctct NM_000088 
FABP4 ggatgataaactggtggtgga cacagaatgttgtagagttcaatgc NM_001442 
APM1 ggtgagaaaggagatccaggt tgctgagcggtatacataggc NM_004797 
LPL agaacatcccattcactctgc ccatttgagcttcaacatgagt NM_000237 
ALP gacggacccgtcactctc gtgcccgtggtcaattct NM_000478 
OP cgcagacctgacatccagt ggctgtcccaatcagaagg NM_000582 
TBP gcccatagtgatctttgcagt cgctggaactcgtctcacta NM_003194 
    
 
SOX9, SRY (sex determining region Y)-box 9; COL2A1, type 2A1 collagen; AGG, Aggrecan; COL1A1, type 1A1 
collagen; FABP4, fatty acid-binding protein 4; APM1, adiponectine; LPL, lipoprotein lipase; ALP, alkaline 
phosphatase; OP, osteopontin; TBP, TATA box binding protein 
  
Table 2 General information of the donors showing flow cytometry results of the cells at the third passage (mean ± SD) 
Phenotypical characterization of the cells 
Donor Years Gender CD73/CD44 
CD105/CD
106 
CD105 CD166 CD29 CD90 CD117 SSSEA4 
           
Media 69 2 M & 1F 94 % ± 0.05 
24 % ± 0.1
4 
96 % ± 
0.12 
92 % ± 0.06 94 % ± 0.03 95 % ± 0.02 23 % ± 0.38 83 % ± 0.09 
           
 
M means male and F means female 
Multi-differentiation potential 
We induced adipogenic, osteogenic and chondrogenic differentiations under normoxic conditions, as 
described in the materials and methods part, in order to confirm the multi-potentiality of our cultured 
expanded cells. 
Adipogenic and osteogenic differentiation 
After 21 days of culture with the appropriate differentiation medium or with DMEM plus 20 % FBS 
serum for the control points, the cells were stained with Oil Red O for lipid droplets to evaluate 
adipogenic differentiation and with Alizarin Red for calcium deposits to evaluate osteogenic 
differentiation. All the controls resulted nearly almost negative for staining, showing the absence of lipid 
droplets and calcium deposits. The cells grown in differentiation medium were positively stained 
(Fig. 1a), indicating differentiation. In the adipogenic and in the osteogenic differentiation, the percentage 
of cells with positive Oil Red O staining and Alizarin Red staining was respectively more than 40 and 60 
times higher than in the control medium (p value <0.05, two-tailed t test) (Fig. 1b). To confirm this result, 
total RNA was extracted from cells treated in the same way, reverse transcribed into cDNA and the 
resulting cDNA was used as template for subsequent qPCR amplification. We measured the expression 
levels of LPL, APM1 and FABP4 marker genes for adipogenic differentiation and of OP and ALP marker 
genes for osteogenic differentiation (Fig. 1c). In each experiment, each gene expression level of cells 
treated with the differentiation medium was compared to cells cultured in DMEM with 20 % FBS 
(control points). Cells treated with adipogenic medium showed higher levels of LPL, APM1 and FABP4 
expressions compared to the control cells (4534.31; 3404.75 and 13369.58 times, respectively) and were 
statistically significant (p value <0.005, two-tailed t test). Cells treated with osteogenic medium showed 
higher levels of OP and ALP expressions compared to the control cells (27.67 and 57.28 times, 
respectively) and were statistically significant (p value <0.05, two-tailed t test). These results confirmed 
the histological stainings. 
  
 
 
 
Fig. 1 Adipogenic and osteogenic differentiation of BM-MSCs grown in adipogenic (ADM) and osteogenic (ODM) differentiation 
medium with their respective control grown in DMEM with 20 % FBS (CTRL) (a). The percentage of cells positive for Oil Red O 
(adipogenic differentiation) and for Alizarin Red (osteogenic differentiation) stain is expressed as the mean ± SE; *p < 0.05 and 
**p < 0.005 (b). The adipogenic and osteogenic differentiation potential was confirmed by qPCR, comparing results to the 
corresponding control. Data are expressed as mean ± SE of the REL (c) 
Chondrogenic differentiation 
After 14 days of culture with the diverse chondrogenic differentiation media or with DMEM plus 15 % 
KO serum for the control cells, the aggregates were analyzed by histochemistry using HE, TB, MT and 
SaO staining, and immunohistochemistry for type I, II and X collagens, and metalloproteinase 13. These 
techniques confirmed chondrogenic differentiation under our experimental conditions (Fig. 2a,b). 
Specifically, TB and SaO showed the presence of extracellular matrix, stained respectively in violet-blue 
and orange-red, mainly in the points corresponding to cells treated with TGFβ-3 10 ng/mL and when 
combination of the three growth factors. By means of histochemistry, the presence of type II collagen and 
proteoglycans were higher in the different chondrogenic differentiation media than in the corresponding 
controls. Immunohistochemistry results for Col1A1, Col10A1 and MMP13 were nearly almost negative 
(data not shown). To confirm this result, total RNA was extracted from cells treated in the same way, 
reverse transcribed into cDNA and the resulting cDNA was used as template for subsequent qPCR 
amplification (Fig. 3). In each experiment, each gene expression level of cells treated with each of the 
chondrogenic differentiation medium was compared to cells cultured in DMEM plus 15 % KO serum 
(control points). We determined the expression levels of different genes involved in chondrogenesis 
corresponding to the mature chondrocyte phenotype (COL2A1, SOX9 and aggrecan) and also COL1A1 
(corresponding to hypertrophic chondrocytes). Treated cells showed higher levels of SOX9 expression 
compared to the control points, obtaining the higher values when the combination TGFβ-3 
1 ng/mL + BMP-2 10 ng/mL + BMP-7 10 ng/mL and also BMP-2 10 ng/mL alone were added as growth 
factors to the culture media (5.13 and 2.51 times, respectively) and were statistically significant (p < 0.05, 
two-tailed t test) when using the combination TGFβ-3 1 ng/mL + BMP-2 10 ng/mL + BMP-7 10 ng/mL. 
However aggrecan and COL1A1 expression levels were only higher than the control points when TGFβ-3 
10 ng/mL was added to the culture media (1.76 times for aggrecan and 1.94 for COL1A1), resulting to be 
statistically significant (p < 0.05, two-tailed t test) for aggrecan. The COL2A1 gene was detected 
(Ct = 27) only when the following combination of growth factors was added: TGFβ-3 1 ng/mL + BMP-2 
10 ng/mL + BMP-7 10 ng/mL. The results of the expression of COL2A1 cannot be shown due to the 
absence of its detection in the other conditions analyzed. 
 
 
 
Fig. 2 Histologic and immunohistochemical analysis of the BM-MSCs chondrogenic differentiation in normoxic conditions. The 
pictures show the results obtained after 14 days of pellet culture with chondrogenic medium plus three different growth factors alone 
or in combination. TGFβ3-1 means 1 ng/mL TGFβ-3; TGFβ3-10 means 10 ng/mL TGFβ-3; BMP2 means 10 ng/mL BMP-2; BMP7 
means 10 ng/mL BMP-7; TGF + BMPs means 1 ng/mL TGFβ-3 + 10 ng/mL BMP-2 + 10 ng/mL BMP-7. All the chondrogenic 
differentiation points were compared to cells grown in DMEM with 15 % KO serum (CTRL). HE, Hematoxylin-eosin; TB, 
toluidine blue; MT, Masson´s trichrome; SaO, safranin O; and Col2A1, type II collagen stainings (a). Percentage of cells positive 
for Col2A1 staining is expressed as the mean ± SE (b) 
  
 
 
 
Fig. 3 Chondrogenic differentiation potential was analyzed by qRT-PCR, comparing the different chondrogenic culture media 
(TGFβ3-1, TGFβ3-10, BMP-2, BMP-7 and TGF + BMPs) with the control grown in DMEM with 15 % KO serum (CTRL). 
Expression levels of SOX9, aggrecan (AGG) and COL1A1 at day 14 of culture in normoxic conditions; *p < 0.05. Data are 
expressed as mean ± SE of the RELs 
Discussion 
Chondrogenic differentiation of MSCs leads to the expression of two chondrocyte hypertrophy-associated 
genes, collagen X and MMP13 as shown by Sekiya et al. (2002) and by Pelttari et al. (2006). Due to this, 
it is imperative to establish the best protocol for in vitro directing stem cell differentiation into the 
chondrogenic lineage in each experimental design. In this study we examined the in vitro chondrogenic 
induction of BM-MSCs by three different growth factors (BMP-2, BMP-7 and TGFβ-3), alone or in 
combination, in normoxic conditions. In all the experiments performed, BM-MSCs from the three donors 
were able to differentiate toward adipogenic, osteogenic and chondrogenic lineage. In addition, qPCR 
analysis of the marker genes for each specific lineage confirmed these results, since it was observed an 
up-regulation of the genes analyzed in the treated cells compared to the corresponding controls. 
In the last years, many studies have been focused on finding better culture conditions capable to 
differentiate MSCs towards mature chondrocytes (Heng et al. 2004). For this purpose different growth 
and differentiation factors were studied in detail by Sekiya et al. (2002) and by Kim et al. (2005). In 
particular, the ability of BMPs to promote chondrogenesis of MSCs and to increase matrix production by 
these multipotent cells have been studied extensively over the past two decades (Kurth et al. 2007; 
Nawata et al. 2005; Kaps et al. 2002; Keller et al. 2011). BMPs are members of the TGFβ superfamily of 
growth and differentiation factors. These proteins, originally identified by Toh as inducers of bone and 
cartilage formation in ectopic sites (Toh et al. 2007), act as autocrine and/or paracrine factors regulating 
bone growth, development and remodeling. It is well-known that bone and cartilaginous cells produce 
BMPs. BMPs induce differentiation of pluripotent mesenchymal cell lines into chondrocytes when grown 
at high density, since high-density culture mimics the condensation step that precedes the chondrogenesis 
in vivo. Kameda reported that BMP-2, -5, and -6 maintain and promote later stages of chondrocyte 
differentiation rather than initiation of maturation (Kameda et al. 2000) while Haaijman that BMP-7, 
which is expressed in proliferating chondrocytes, promoted chondrocyte proliferation and inhibited 
terminal differentiation (Haaijman et al. 2000). BMP-2 regulates the chondrogenic differentiation, the 
maturation of mesenchymal progenitors and stimulates the synthesis of chondrocyte matrix components, 
as described by Toh et al. (2007). For this reason BMP-2 has been proposed as a tool for cartilage repair 
and as an inducer of chondrogenesis. In healthy cartilage, Blaney assessed that BMP-2 is hardly present, 
whereas it is highly expressed during osteoarthritis (Blaney Davidson et al. 2007). In our study, and 
regarding chondrogenic differentiation, we obtained the better chondrogenic induction when the 
combination TGFβ-3, BMP-2 and BMP-7 of growth factors was added to the culture medium, since it 
was the unique culture condition that showed COL2A1 gene expression and that revealed the highest 
SOX9 expression level. Likewise, chondrogenic culture medium containing only BMP2 also showed high 
SOX9 mRNA expression levels. This result is in agreement with those published by Nawata et al. (2005) 
and Toh et al. (2007). The former generated cartilage tissue by inducing the in vivo differentiation of rat 
muscle-derived cells into the chondrocytic lineage with recombinant human bone morphogenetic protein 
2 (rHuBMP-2). The latter demonstrated that the high-density 3D micromass culture condition, in 
combination with BMP-2, resulted in an enhancement and enrichment of chondrogenic differentiation. 
Combinations of growth factors have also been used in the past to promote chondrogenic 
differentiation of MSCs. Xiang et al. (2007) induced the chondrogenesis of MSCs using the combination 
of IGF-1 (insulin-like growth factor-1) and TGFβ-1; whereas Kim and Im (2009) demonstrated that 
administration of a combination of TGFβ-2 and BMP-7 was the most effective in promoting 
chondrogenesis. 
Both COL2A1, that encodes a key cartilage-specific extracellular matrix protein, and SOX9, that 
encodes a nuclear transcription factor, are two of the earlier markers expressed during chondrogenesis. 
SOX9 is required for the differentiation of chondroprogenitors towards mature chondrocytes and for the 
deposition of cartilage matrix containing collagens II, IX, XI and aggrecan, as described by Lefebvre et 
al. (1997). This transcription factor is expressed continuously in chondrocytes up to the hypertrophic 
stage and is required not only to maintain the chondrocyte phenotype but also for BMP induced 
chondrogenesis, as described by Yoon and Lyons (2004). In all the chondrogenic media tested we 
observed, by immunohistochemistry, the presence of type II collagen immunoreactivity in the 
extracellular matrix, however mRNA transcript level of collagen II was only detected when the 
combination TGFβ-3, BMP-2 and BMP-7 was added. This absence of type II collagen mRNA expression 
in the other culture conditions analyzed may be due to the destabilization during the translation of some 
mRNAs with AU-rich elements as described by Lian et al. (2007). 
Aggrecan is one of the more abundant proteoglycans in the hyaline articular cartilage, as reported by 
Heinegard (2009). This large proteoglycan consists of a 200 kDa core protein to which keratin sulphate 
and chondroitin sulphate glycosaminoglycan side-chains are attached. During chondrogenesis, agreccan 
mRNA begins to accumulate at the onset of cellular condensation and continues to be expressed 
throughout differentiation. In our study, we observed the highest aggrecan mRNA expression level when 
TGFβ-3 10 ng/mL alone or the combination TGFβ-3, BMP-2 and BMP-7 of growth factors were added to 
the chondrogenic culture medium. Regarding the use of TGFβ-3 alone, the work by Kim (2005) 
demonstrated that cells derived from human embryonic germ cells differentiate toward chondrogenic 
lineage when they are culture in the presence of this transforming growth factor. These authors 
demonstrated that accumulation of proteoglycans, not only in cell pellets but also in culture medium, was 
increased by TGFβ-3 treatment. This proteoglycan release was maintained higher in cells treated with 
TGFβ-3 than in the controls without treatment, suggesting chondrogenic differentiation. However, after 
21 days of culture control-cell pellets without treatment and cell pellets treated with BMP-2 alone or co-
treated with BMP-2 and TGFβ-3, showed a similar proteoglycan release. On the other hand, it has been 
demonstrated that BMP-2 and BMP-7 promote cartilage differentiation and matrix maturation in artificial 
engineered cartilage tissues in vitro. In this sense, Kaps et al. (2002) demonstrated that BMP-7-expressing 
chondrocytes are able to promote and maintain the chondrocyte phenotype by inverting the collagen 
expression profile from type I collagen to type II collagen during prolonged cultivation in vitro. On the 
contrary, BMP-2-expressing chondrocytes showed no alteration in collagen gene expression compared 
with control-transfected chondrocytes still displaying a de-differentiated phenotype, surprisingly in these 
cells the expression of the large cartilage proteoglycan aggrecan was slightly down-regulated. 
Conclusions 
In our experimental conditions the three growth factors used, alone or in combination, were capable to 
induce the beginning of chondrogenesis in normoxia environment. Nevertheless, the chondrogenic culture 
condition that better induced BM-MSCs chondrogenesis was the one that included the combination of the 
three growth factors tested followed by the medium with the higher concentration of TGFβ-3. In our 
experimental conditions, we have determined the best method for in vitro studying BM-MSCs efficient 
chondrogenesis in normoxia conditions. This method could provide a powerful tool for study the 
contribution of specific genes to the process of chondrogenesis. 
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